drugset
drugset / Trial / NCT03773835

A Study Evaluating Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Single IV Dose of HSK3486 Injectable Emulsion in Healthy Subjects.

NCT03773835 ↗

Phase 1 Completed 24 enrolled Sichuan Haisco Pharmaceutical Group Co., Ltd
SequentialOpen-labelTreatment

Summary

his single-center, open-label, uncontrolled, and dose-escalation study evaluated the safety, tolerability, and pharmacokinetics/pharmacodynamics of single IV dose of HSK3486 injectable emulsion in healthy subjects.

Timeline

Start
2016-05
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cipepofol Small molecule 0.15 mg/kg Intravenous
Subject Cipepofol Small molecule 0.4 mg/kg Intravenous
Subject Cipepofol Small molecule 0.6 mg/kg Intravenous
Subject Cipepofol Small molecule 0.9 mg/kg Intravenous

Indications

No indication recorded.